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Abstract
Background: Postoperative fever may serve as an indirect sign to reflect the alterations of the host milieu caused by
surgery. It still remains open to investigation whether postoperative fever has a bearing on prognosis in patients with lymph
node negative breast cancers.
Methods: We performed a retrospective study of 883 female unilateral patients with lymph node negative breast cancer.
Fever was defined as an oral temperature $38 in one week postoperation. Survival curves were performed with Kaplan-
Meier method, and annual relapse hazard was estimated by hazard function.
Findings: The fever patients were older than those without fever (P,0.0001). Hypertensive patients had a propensity for
fever after surgery (P=0.011). A statistically significant difference was yielded in the incidence of fever among HR+/ERBB2-,
ERBB2+, HR-/ERBB2- subgroups (P=0.012). In the univariate survival analysis, we observed postoperative fever patients were
more likely to recur than those without fever (P=0.0027). The Cox proportional hazards regression analysis showed that
postoperative fever (P=0.044, RR=1.89, 95%CI 1.02–3.52) as well as the HR/ERBB2 subgroups (P=0.013, HR=1.60, 95%CI
1.09–2.31) was an independent prognostic factor for relapse-free survival.
Conclusion: Postoperative fever may contribute to relapse in node negative breast cancer patients, which suggests that
changes in host milieu related to fever might accelerate the growth of micro-metastatic foci. It may be more precise to
integrate both tumor- and host-related factors for the evaluation of relapse risk.
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Introduction
Worldwide, more than a million women are diagnosed with
breast cancer every year, accounting for 27% of all female new
cases in the United States in 2009 [1]. The incidence rates of
breast cancer vary considerably, with the highest rates in the
North America and the lowest rates in Africa and Asia. However,
the number of new breast cancer cases has risen dramatically in
developing countries, especially in China over recent years [1,2],
which mainly results from the aging of society and changes of
lifestyle. On the other hand, the development of imaging
techniques also contributed to the increased diagnosis of earlier
breast cancer patients, most of whom were featured by negative
axillary lymph node (ALN) [3,4,5].
Women with ALN negative breast cancers have a relatively
good prognosis. However, approximately 20% of these patients
will experience disease recurrence and subsequent death, even if
some of them may benefit from adjuvant systemic therapy [6].
Nowadays, various guidelines are available for risk allocation to
determine the optimal therapeutic modality in node-negative
women [7,8]. Over the past years, a number of clinicopathological
parameters have been regarded as potential prognosticators in
patients with early-stage node-negative breast cancer, exemplified
by tumor size, histological grade, cathepsin-D status, p53
mutation, ERBB2 overexpression, Ki-67 index, S-phase fraction,
mitotic index, and vascular invasion etc. [6,9,10]. Besides, some
multigene assays have also been validated to provide useful
information for women with node-negative breast cancers
[10,11,12,13]. The 21-gene Recurrence Score (RS) assay (Onco-
type DX, Genomic Health, Redwood city, CA) is one of the best
tools along with the pathology to help quantify the risk of distant
recurrence as well as predict the magnitude of chemotherapy
benefit in tamoxifen-treated patients with lymph node-negative,
estrogen receptor(ER)-positive breast cancer [11,13,14]. Unfortu-
nately, all the factors above are confined to tumor biology per se
and have been described in an extensive body of literature, while
the impact of the host’s internal environments on clinical outcomes
still remains unclear and open to investigation.
It has long been recognized that the development and
progression of a certain cancer is the consequence of dynamic
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environments. Two centuries ago Paget proposed the ‘‘seed and
soil’’ hypothesis, which states that specific organs (the ‘‘soil’’)
harbor metastases from selected cancer cells (the ‘‘seeds’’) [15].
The potential of tumor cells to colonize and propagate depends on
their cross-talk with the extracellular matrix components of the
distant organ. By this token, what can influence the host milieu
may somewhat modify the course of the disease. Surgery, as a
stimulus to the host, has been demonstrated at least partially to be
responsible for such effect. Manifold studies revealed that primary
tumor removal might lead to sudden acceleration of metastatic
process by releasing the growth factor into the blood [16], which
indicated that surgical extirpation is not just a local phenomenon
without any other biological consequences. Accordingly, a better
knowledge of host responses induced by surgery may contribute to
a fuller perspective of prognostic profiles in breast cancer patients.
Postoperative increased core temperature is one of the host
responses to surgery. Despite its prevalence in postoperative
patients, the logics behind it are still poorly understood. The most
frequently observed etiology of fever after surgery is related to the
normal thermoregulatory response without infection [17]. There-
fore, postoperative fever may serve as an indirect sign to reflect the
alterations of the host milieu caused by surgery.
On these premises, we sought to probe into the possible
correlation between postoperative fever and survival times.
Nowadays, few studies have been conducted to bring it to light
in breast cancer patients. However, only one small study observed
that the relative risk of recurrence after postoperative fever
increased significantly [18]. That study retrospectively included
378 breast cancer patients of all stages, which failed to mirror the
true picture of postoperative fever since its role might be shadowed
by sufficiently established prognostic factors such as ALN status.
Accordingly, a retrospective analysis was carried out among
ALNs-negative breast cancer patients undergoing surgery in
Fudan University Shanghai Cancer Center, Shanghai, China,
offering the implications for the underlying mechanism.
Methods
Patients
A total of 883 node-negative breast cancer patients were
selected retrospectively from a large database of patients who
underwent surgery between January 1, 2000 and December 31,
2002 in Fudan University Shanghai Cancer Center, Shanghai,
China. Before surgery, such evaluations were mandatory for each
patient as complete physical examination, chest radioscopy,
bilateral mammography, ECG, ultrasonography of breasts, aillary
fossa, cervical parts, abdomen and pelvis, complete blood count,
and routine biochemical tests to make an exact staging. Each
patient received lumpectomy or mastectomy followed by adjuvant
therapy according to the guidelines or recommendations used at
the time of surgery. Patients with bilateral primary breast cancer
and/or with initial systemic metastases were excluded from the
study. The body temperature was measured with an oral
thermometer three times a day for each patient. A fever was
defined as one measured oral temperature $38uC in one week
postoperation, which was similar to other relevant reports [19,20].
Follow-up information regarding tumor recurrence and survival
status was accomplished through the retrieve of medical records
kept in the outpatient department, personal contact with the
patient as well as the assistance of Shanghai Center for Disease
Control and Prevention (CDC). Personal contact with the patient
referred to routine correspondence or telephone visits, which were
carried out in Fudan University Shanghai Cancer Center every 3
months during the first two years, every 6 months during the next
two years and once a year thereafter. Recurrence or its absence
was diagnosed by query to the patient, by biopsy, or by scan of
bone, chest, abdomen, pelvis or skull. Whenever the tumor
recurred, additional information, including sites of recurrence and
therapy, was requested.
Ethical appraisal from Medical Ethics Committee at Fudan
University Shanghai Cancer Center was exempt for the
retrospective study involving the collection or analysis of existing
data in accordance with federal regulations 45 CFR 46 [21]. And
therefore, written consent given by the patients was not needed for
their hospitalization and follow-up information to be stored in the
center database and used for research. Furthermore, we only took
anonymous data from this database and the Ethics Committee
waived the need for approval and consent.
Immunohistochemistry
Immunohistochemical staining was carried out as a standard
operating procedure in the pathology department of Fudan
University Shanghai Cancer Center. All primary monoclonal
antibodies for estrogen receptor (ER), progesterone receptor (PR)
and ERBB2 were from Dako. The staining results were assessed by
at least two pathologists, using a semiquantitative scoring system,
where integrated the proportion score and the intensity score. The
proportion score, indicating the percentage of tumor cells stained,
was interpreted such that a score of 0 required no staining seen, 1
required #25% of cells positive, 2 required 25–50% of cells
stained, 3 required 50–75% of positive cells and 4 required .75%
of staining cells. As to the intensity score, a negative result was
defined as a score of 0, weakly positive as 1, moderately positive as
2, and strongly positive as 3. The final score was calculated as the
product of the proportion score and the intensity score. Thereby,
staining results ranged from score 0 to 12.The scoring system for
ER and PR was defined as negative for score 0 and positive for
scores of 1,12 with the nucleic staining of carcinoma cells,
whereas ERBB2 was defined as negative for scores of 0,8
(namely, 0, 1+ and 2+ in the DAKO scoring system) and positive
for strong membranous staining with scores of 9,12 (namely
DAKO score 3+).
Statistical analysis
Relapse-free survival (RFS) was defined as the time from surgery
to the earliest occurrence of recurrence (loco-regional or distant) or
death from any cause. Those without any evidence of relapse were
censored at the last date they were known to be alive.
Clinicopathological parameters were compared between different
subgroups using student’s t test for continuous variables and chi-
square test for categorical variables.
Survival curves were performed by the Kaplan–Meier method
and were compared using the log-rank test. Multivariate Cox
proportional hazards regression analysis was applied to modeling
the relationship between postoperative fever and RFS, adjusted for
age (#50 years, .50 years), tumor size (#5 cm, .5 cm), history
of hypertension (yes, no), type of surgery (mastectomy, breast
conservative surgery) as well as the hormone receptor HR/ERBB2
subgroups (HR+/ERBB2-, ERBB2+, HR-/ERBB2- or triple
negative). Relative risks (RRs) were presented with their 95%
confidence intervals (CIs). For graphical display of RFS, annual
hazard rates were estimated using a Kernel method of smoothing.
All the analyses were considered statistically significant when the
P-value was less than 0.05. All statistical analyses were performed
with Stata statistical software package (release 10.0; Stata
Corporation, College Station, Texas, USA).
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General characteristics
The median age of the 883 patients was 52 years old (range
25,91) at diagnosis. Among the study population, 230 patients
(26.05%) suffered from postoperative fever. The patients with
postoperative fever tended to be older than those without fever
(55.07611.56 vs. 51.38611.23, P,0.0001). ERBB2+ patients
were more likely to develop postoperative fever than HR+/
ERBB2- and triple negative subgroup (42.62%, 21.71% and
27.41% respectively, P=0.003). There was a significantly
increased incidence of postoperative fever in hypertensive patients
than those with normal blood pressure (33.00% vs. 24.01%,
P=0.011). In addition, such was likewise the case for the patients
undergoing mastectomy and breast conservation surgery (27.47%
vs. 12.20%, P=0.003). When compared to patients without fever
after surgery, more relapse events were observed in those who
have postoperative fever (P=0.004) with a median follow-up of 43
months (range 3–90 months) (Table 1).
Survival analysis
In the univariate survival analysis, we found significantly
different RFS between patients with and without postoperative
fever (P=0.0027) (Figure 1), with the rate of 88.18% for the
former and 93.94% for the later at the 5th year. Besides, a similar
effect was also noted among different HR/ERBB2 subgroups
(P=0.012) (Figure 2A), while marginal significance was achieved
between patients with larger and smaller tumors (P=0.0581)
(Figure 2B).
In Cox proportional hazards regression analysis, we found that
HR/ERBB2 subgroup (P=0.013; RR=1.60; 95%CI 1.90–2.31)
and fever (P=0.044; RR=1.89; 95%CI 1.02–3.52) were inde-
pendent prognostic factors for RFS (Table 2).
Relapse hazard analysis
As to hazard peaks, discrepancies existed in different subgroups.
The hazard plots displayed the long-term benefit in risk reduction
for women without fever over those suffering from fever
throughout the entire follow-up period. Patients with postoperative
fever exhibited a modest increase from 25 to 40 months, whereas
the hazard rate for those without fever showed an early major
relapse surge peaking at the 45th month after surgery (Figure 3).
Discussion
Our study is, to the best of our knowledge, the first and the
largest retrospective analysis on the relationship between postop-
erative fever and prognosis in node negative breast cancer patients.
Following breast cancer surgery, various complications arise, such
as flap necrosis, infection, seroma formation, fever. Murthy and
colleagues [22] reported that there was an increased risk of
systemic recurrence in patients with wound problems at primary
surgery, which indicated that host responses to the surgery,
Table 1. Summary of patient’s characteristics and its
association with postoperative fever.
Variable Univariate analysis, n(%) P value
Fever No fever
Mean Age at Diagnosis (year, x6SD) 55.07611.56 51.38611.23 ,0.0001
Age at diagnosis
#50 years
.50 years
79(34.35)
151(65.65)
365(55.90)
288(44.10)
,0.0001
Tumor size
#5c m
.5c m
222 (96.52)
8(3.48)
630 (96.48)
23(3.52)
0.975
HR/ERBB2 Subgroup
HR+/ERBB22
ERBB2+
HR-/ERBB22
Unknown
66(28.70)
26(11.30)
111(48.26)
27(11.74)
238(36.45)
35(5.36)
294(45.02)
86(13.17)
0.003
Type of Surgery
Breast conservation surgery
mastectomy
10(4.35)
220(95.65)
72(11.03)
581(88.97)
0.003
Hypertension
Yes
No
66(28.70)
164(71.30)
134(20.52)
519(79.48)
0.011
Relapse events
Yes
No
21(9.13)
209(90.87)
27(4.13)
626(95.87)
0.004
doi:10.1371/journal.pone.0015903.t001
Figure 1. Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by postoperative fever.
doi:10.1371/journal.pone.0015903.g001
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clinical outcomes. However, such studies were almost confined to
surgical incision complications while excluding postoperative
fever.
As a complex systemic defense reaction of the host, fever refers
to a rise in core temperature with resultant release of specific
cytokines induced by infection, injury, surgical and general
anesthesia trauma [23,24,25,26]. Cytokines have been implicated
as pivotal mediators of the pyrogenic or antipyretic process,
including the pro-inflammatory tumor necrosis factor a (TNF-a),
interleukin-6 (IL-6) and interleukin-1 (IL-1) as well as the anti-
inflammatory interleukin-1 receptor antagonist (IL-1ra) and
interleukin-10 (IL-10) [27]. The levels of cytokines with opposite
function decide the occurrence and magnitude of fever and vice
versa. Surgical and anaesthetic stress may elicit the imbalance
between the pro- and anti- inflammatory cytokines leading to fever
[27]. A large body of reports demonstrated the stimulatory role for
TNF-a, IL-1 and IL-6 in the proliferation of breast tumors
Figure 2. Kaplan–Meier curves for RFS in 883 ALN negative breast cancer patients by HR/ERBB2(A) and tumor size (B).
doi:10.1371/journal.pone.0015903.g002
Table 2. Multivariate Cox proportional hazards regression
analysis for RFS in 883 ALN negative breast cancer patients.
Variable RR 95% CI of RR P value
Fever 1.89 1.02–3.52 0.044
Age(#50 vs..50) 1.77 0.89–3.50 0.102
Type of surgery 0.49 0.19–1.29 0.148
Hypertension 0.66 0.31–1.38 0.268
Tumor size(#5c mvs..5 cm) 2.19 0.67–7.18 0.194
HR/ERBB2 subgroup 1.60 1.09–2.31 0.013
doi:10.1371/journal.pone.0015903.t002
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inflammatory cytokines might cooperate to exacerbate the pre-
existing subclinical lesions and accordingly promote recurrence
and death in patients with postoperative fever, which might
elucidate the detrimental effect of fever on prognosis in this
analysis as well as other relevant reports [18,31].
On the other hand, cytokines may also confer the resistance to
routine systemic treatment. In in vitro studies, the autocrine
production of IL-6 by tumor cells increased the resistance to
chemotherapy [32]. What’s more important, Zhang and cowork-
ers [33] detected significantly higher serum IL-6 levels in patients
unresponsive to chemo-endocrine therapy than the responsive
counterparts (P=0.0007) in metastatic breast cancer patients.
Besides, higher IL-6 level was also associated with poorer survival.
These data indicate that such cytokines may affect the respon-
siveness of cancer cells to pharmaceutical agents, which conduce
to the generation of drug-resistant strains, constituting the origin of
recurrence. On the basis of the findings above, these cytokines
bridge the fever after surgery and the progression of cancer in a
direct and indirect way, which may serve as novel targets in cancer
therapy.
The study has some potential limitations because it is a
retrospective study. For a substantial portion of the patients in this
database, relpases are probably somewhat underreported or
misinformed; however, underreporting or misinformation of
relapses would have not varied by clinicopathological parameters.
Because of the retrospective nature of this study, our findings are
for hypothesis generation only and need to be confirmed in large
prospective studies.
Our results suggest that postoperative fever is associated with an
increased rate of relapse in primary breast cancer patients. Apart
from conventional prognosticators including ALN status, postop-
erative fever may also be a pivotal indicator in terms of host
response, which will help to improve the accuracy of predicting
prognosis and discover a new strategy of treatment.
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